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Abstract
Background: Patients with type 2 diabetes are at increased risk of cardiovascular events, and there is an associated
economic burden attached to this risk. We conducted a retrospective claims database analysis to evaluate incremental
cardiovascular costs in diabetic versus non-diabetic patients hospitalized for a cardiovascular event.
Methods: Patients hospitalized for a cardiovascular event between January 1, 2001 and June 30, 2005 were identified
from a large US managed-care population. Diabetic patients were identified by evidence of type 2 diabetes in the 12
months prior to the index hospitalization. Direct medical costs and resource use - including inpatient expenditures (for
the index and first recurrent hospitalizations), as well as outpatient, laboratory, and pharmacy expenditures (during the
3-year follow-up period) - were determined for patients with or without diabetes.
Results: Of the 29,863 patients identified with a cardiovascular hospitalization, 5,501 patients (18.4%) had a history of
diabetes in the pre-index period (mean age, 57.8 years; 42.1% female). The overall mean follow-up period was 22.8
months. The incidence of subsequent cardiovascular events in the first year of follow-up was significantly higher for
patients with diabetes compared with non-diabetic patients for all types of cardiovascular events except angina.
Compared with non-diabetic patients, patients with diabetes had similar mean direct medical costs per patient for the
index cardiovascular hospitalization ($17,435 versus $16,917; P  = 0.09), and the first recurrent cardiovascular
hospitalization ($18,488 versus $17,481; P = 0.2), yet higher mean total direct medical costs per patient for cardiovascular
events during follow-up years (Year 1: $8,805 versus $6,982; Year 2: $13,860 versus $10,056; Year 3: $16,149 versus
$12,163; all P ≤ 0.0002). The cost difference between diabetic and non-diabetic patients remained significant after
adjusting for age, gender and other potential confounders in multivariate regression analysis. The mean (SD) total period
of inpatient cardiovascular hospitalization after 3 years of follow-up was 3.3 (12.4) days for patients with diabetes
compared with 1.8 (5.8) days for non-diabetic patients (P < 0.0001).
Conclusion: Diabetic patients hospitalized for a cardiovascular event incur higher costs for cardiovascular care than
their non-diabetic counterparts. This analysis of the incremental cardiovascular cost and resource use provides the basis
for greater accuracy and precision when modeling the economic value of initiatives aimed at reducing cardiovascular
morbidity in patients with diabetes mellitus.
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Introduction
Approximately 17.5 million people in the United States
have recognized diabetes, with an estimated 1 million
new cases diagnosed each year [1]. Diabetes is a well-
established risk factor for future cardiovascular events [2],
including coronary heart disease (CHD), ischemic stroke,
and peripheral vascular disease. Of the ~284,000 deaths
in 2007 attributed to diabetes and its associated complica-
tions, nearly 65% were due to cardiovascular or cerebrov-
ascular causes [1]. Indeed, the presence of diabetes can
increase the risk of CHD and stroke by as much as 5-fold
[3-6], in addition to conferring a worse prognosis for sur-
vival from a cardiovascular event [7-10]. As such, diabetes
is currently regarded as a CHD risk equivalent [11,12] and
recommendations for aggressive risk factor management
in the diabetic population reflect this high-risk status [13].
Given the prevalence of diabetes and the morbidity and
mortality associated with it, the burden the disease
imposes on the US economy is considerable: the total cost
of diabetes in 2007 was estimated at $116 billion in med-
ical expenditures and an additional $58 billion in lost
productivity [1]. Patient-level estimates of the cost of car-
diovascular care in diabetic populations are critical for
pharmacoeconomic modeling and guiding decisions on
disease management in this cohort. Although previous
studies have investigated the impact of cardiovascular dis-
ease (CVD) on health-care costs for diabetes [14-20], few
contemporary analyses have determined incremental car-
diovascular costs among diabetic versus non-diabetic
patients with pre-existing CVD, particularly those costs
associated with specific types of cardiovascular events
such as coronary artery bypass graft (CABG) procedures,
myocardial infarction (MI), and ischemic stroke.
Therefore, using claims data representative of a large US
managed-care population, we assessed the direct medical
costs and resource use associated with initial and subse-
quent cardiovascular episodes in patients with or without
diabetes hospitalized for a cardiovascular event.
Methods
Data source and claims
This retrospective cohort analysis assessed transactional
billing records from the PharMetrics Patient-Centric Data-
base, which contains fully adjudicated medical and phar-
maceutical claims for > 50 million unique patients from >
90 health-care plans across the United States.
The database includes both inpatient and outpatient diag-
noses (based on International Classification of Diseases,
9th Revision, Clinical Modification [ICD-9-CM] codes)
and procedures (based on Current Procedural Terminol-
ogy 4 [CPT-4] and Health Care Financing Agency Com-
mon Procedure Coding System [HCPCS] codes), in
addition to both retail and mail-order prescription
records (including Generic Product Identifier [GPI]
codes). Both paid and charged amounts are available for
all services rendered, as well as dates of service for all
claims. Additional data elements include demographic
variables (eg, age, gender, geographic region), product
type (eg, Health Maintenance Organization, Preferred
Provider Organization), payor type (eg, commercial, self-
pay), provider specialty, and start and stop dates for plan
enrollment. Only health-care plans that submit data for
all plan members are included in the database, ensuring
complete data capture and representative samples. Contri-
butions are also subjected to a series of data quality checks
to ensure a standardized format and minimal error rates.
Study period
The overall study period was from January 1, 2001 to June
30, 2006. The patient identification period was from Jan-
uary 1, 2001 to June 30, 2005. The first hospitalization
with relevant diagnosis or procedure codes for a cardio-
vascular event during the identification period was
defined as the index hospitalization. The pre-index period
was defined as the 12 months prior to the index hospital-
ization admission date. The post-index (follow-up)
period began 1 day after the discharge date of index hos-
pitalization. The follow-up period was stratified to define
3 cohorts of patients with 1, 2, or 3 years of continuous
enrollment after the index hospitalization discharge date.
Follow-up terminated at the earliest of patient disenroll-
ment or June 30, 2006. Patients who died during the study
were included in the analysis regardless of length of fol-
low-up.
Identification of study cohorts
The patient selection procedure is shown in Figure 1.
Patients with a complete hospitalization (admission and
live discharge within the identification period) for a cardi-
ovascular event between January 1, 2001 and June 30,
2005 were identified from the claims database on the
basis of ICD-9-CM diagnosis codes and CPT-4 procedure
codes (see Additional File 1). Inclusion in the final study
cohort required patients to be continuously enrolled for
the entire pre-index and follow-up periods, to not have a
cardiovascular-related claim in the pre-index period, to
have an index hospitalization stay ≤ 27 days, and to be ≥
18 years of age at index hospitalization. Diabetic patients
were identified by evidence of type 2 diabetes in the pre-
index period (diagnosis of type 2 diabetes or antidiabetic
medication use; Additional file 1).
Cost analyses and resource utilization
All medical, laboratory, and pharmacy claims were
assessed for the identified patients for the period from
January 1, 2000 to June 30, 2006. Direct medical costs
included any cost incurred during an inpatient hospitali-Cardiovascular Diabetology 2009, 8:53 http://www.cardiab.com/content/8/1/53
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The study cohort identification procedure with the final study cohort stratified by history of type 2 diabetes in the 12 months  prior to hospitalization. CV, cardiovascular Figure 1
The study cohort identification procedure with the final study cohort stratified by history of type 2 diabetes in 
the 12 months prior to hospitalization. CV, cardiovascular. Figure provides an overview of the patient identification 
procedure with reasons for inclusion/exclusion through the selection process.
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zation associated with a cardiovascular event. If a cardio-
vascular event was the primary diagnosis in any
hospitalization (index or readmission), all costs from that
hospitalization were attributed to that cardiovascular
event and used in the calculation of costs. Costs were
summed from the admission date to the discharge date for
the hospitalization. Mean per patient costs were calcu-
lated for direct medical costs associated with the index car-
diovascular event, direct medical costs associated with the
first recurrent cardiovascular event, and total direct medi-
cal costs for cardiovascular events during the follow-up
period. The mean hospital length of stay (LOS) associated
with each cardiovascular event was also determined.
Direct medical costs and resource utilization were calcu-
lated for all cardiovascular event types combined as well
as stratified by specific cardiovascular event types (eg,
CABG, MI, ischemic stroke); total direct medical costs dur-
ing the follow-up period were also stratified by type of
service (eg, inpatient, outpatient, pharmacy). Costs are
reported in US dollars adjusted for inflation to 2006 using
the medical care component of the Consumer Price Index.
Subsequent cardiovascular events following discharge
from the index hospitalization were assessed by identify-
ing complete hospitalizations during the follow-up
period with the relevant diagnosis or procedure codes for
a cardiovascular event (Additional file 1) to calculate the
incidence of subsequent cardiovascular events during the
first year of follow-up.
Statistical methods
Mean and SD were calculated for continuous variables;
frequency was calculated for categorical variables. Contin-
uous outcome variables were compared using a t-test of
means, and categorical outcome variables were compared
using a Chi Square test. Multivariable regression analysis
was performed using generalized linear models (GLM)
with total cardiovascular-related costs after 1-year follow-
up as the dependent variable, adjusting for age, gender,
geographic region, insurance type, physician specialty and
relevant co-morbidities, including diabetes status. Statisti-
cal analyses were conducted using the SPSS® (SPSS Inc,
Chicago, IL) and SAS® (SAS Institute Inc, Cary, NC) soft-
ware suites.
Results
Study cohorts
A total of 198,961 patients were identified as having a
hospitalization for a cardiovascular event between Janu-
ary 1, 2001 and June 30, 2005 (Figure 1); of these, 29,863
patients were eligible for inclusion in the final study
cohort. Exclusion from the study was due primarily to the
requirement of continuous enrollment for the entire pre-
index period and for 360 days in the post-index period,
and to not have a cardiovascular-related claim in the pre-
index period. Within this overall study population, 5,501
patients (18.4%) were identified as having a history of
type 2 diabetes in the 12 months prior to hospitalization
(Figure 1).
Baseline demographics and clinical characteristics
The baseline demographics and clinical characteristics of
the study cohorts are shown in Table 1. Overall, the
patient population primarily consisted of commercially
insured patients belonging to either a Health Mainte-
nance Organization or Preferred Provider Organization
health-care plan. The mean (SD) follow-up period was
22.8 months. Compared with non-diabetic patients and
the study population overall, the cohort of patients with
diabetes was slightly older, comprised more women, and
had a higher incidence of comorbidity on the basis of the
Charlson Comorbidity Index score and prevalence of
hypertension and dyslipidemia (Table 1). As such,
patients with diabetes were more likely to be taking lipid-
lowering and antihypertensive medications. The cardio-
vascular event type at index hospitalization was similar
across the study cohorts, with the exception of MI (lower
incidence in diabetic patients) and heart failure (higher
incidence in diabetic patients).
Impact of diabetes on incidence of subsequent 
cardiovascular events
The proportion of patients in each study cohort experienc-
ing a subsequent cardiovascular event during the first year
of follow-up is shown in Table 2. Patients with diabetes
had a higher incidence of each specific cardiovascular
event at 1 year of follow-up than patients without diabetes
(Table 2). The incidence of subsequent cardiovascular
events in the first year of follow-up was significantly
higher for patients with diabetes compared with non-dia-
betic patients for all types of cardiovascular event exclud-
ing angina (all P ≤ 0.03).
Impact of diabetes on health-care costs
In the 12 months prior to the index cardiovascular hospi-
talization, patients with diabetes incurred higher total
health-care costs per patient (mean [SD]: $8,394
[$18,549]) compared with non-diabetic patients ($4,405
[$12,037]; P < 0.0001).
Diabetic patients had similar direct medical costs per
patient for the index cardiovascular hospitalization
(mean [SD]: $17,435 [$21,613]) than patients without
diabetes ($16,917 [$20,342]; P = 0.09) (Table 3). An anal-
ysis of the specific type of cardiovascular event underlying
the index hospitalization showed that, compared with
those without diabetes, patients with diabetes had higher
costs for those hospitalizations associated with CABG pro-
cedures, MI, angina, other ischemic heart disease (e.g. cor-
onary atherosclerosis), and peripheral vascular diseaseCardiovascular Diabetology 2009, 8:53 http://www.cardiab.com/content/8/1/53
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(Table 3). For both study cohorts, the highest index hos-
pitalization costs were incurred for hospitalizations
related to CABG procedures (diabetics: $60,385
[$38,622]; non-diabetics: $55,004 [$32,109]), followed
by hospitalizations for MI and other cardiovascular proce-
dures (eg, non-CABG revascularizations) (Table 3).
For the first recurrent cardiovascular hospitalization,
mean (SD) direct medical costs per patient were $18,488
($22,014) for patients with diabetes, compared with
$17,481 ($22,895) for non-diabetics (P = 0.2) (Table 4).
Diabetic patients had higher costs for recurrent hospitali-
zations associated with other cardiovascular procedures,
MI, other ischemic heart disease, ischemic stroke, and
peripheral vascular disease (Table 4). As with the index
hospitalization, the highest recurrent hospitalization
costs for all study cohorts were for hospitalizations related
to CABG procedures (diabetics: $43,404 [$28,686]; non-
diabetics: $47,110 [$39,612]) (Table 4).
Mean total cumulative direct medical costs per patient for
cardiovascular events across 3 years of follow-up are
shown in Table 5 and Figure 2. With the exception of costs
associated with CABG procedures in the second year of
follow-up, diabetic patients incurred higher costs for fol-
low-up care for all cardiovascular event types assessed
than patients without diabetes (Table 5). The highest fol-
low-up costs for both study cohorts were incurred for MI
and other cardiovascular procedures. Follow-up costs
were generally driven by inpatient hospitalization costs
(LOS) as well as costs associated with outpatient care (eg,
physician office visits, imaging tests), particularly in dia-
Table 1: Baseline demographics and clinical characteristics of the study cohort overall and by diabetic status
Parameter All Patients
(n = 29,863)
Patients with Diabetes*
(n = 5,501)
Patients without Diabetes*
(n = 24,362)
P-value‡
Age, mean (SD), years 55.54 (12.05) 57.83 (11.00) 55.03 (12.22) < 0.0001
Female, n (%) 11,097 (37.2) 2,316 (42.1) 8,781 (36.0) < 0.0001
Follow-up, mean (SD), days 694 (348) 687 (353) 695 (347) 0.12
Plan type, n (%) < 0.0001
HMO 12,167 (40.7) 2,444 (44.4) 9,723 (39.9)
PPO 11,356 (38.0) 1,941 (35.3) 9,415 (38.6)
Unknown 306 (1.0) 48 (0.9) 258 (1.1)
Plan payer type, n (%) < 0.0001
Commercial 22,270 (74.6) 3,841 (69.8) 18,429 (75.6)
Medicare risk 4,199 (14.1) 974 (17.7) 3,225 (13.2)
Unknown 1,587 (5.3) 222 (4.0) 1,365 (5.6)
CCI, mean (SD) 0.56 (1.12) 1.61 (1.22) 0.32 (0.94) < 0.0001
Pre-index comorbidities, n (%)
Hypertension 11,648 (39.0) 3,408 (62.0) 8,240 (33.8) < 0.0001
Dyslipidemia 8,976 (30.1) 2,642 (48.0) 6,334 (26.0) < 0.0001
Diabetes 5,501 (18.4) 5,501 (100.0) 0 (0.0) -
Pre-index medications, n (%)
Statins 4,749 (15.9) 1,708 (31.0) 3,041 (12.5) < 0.0001
ACE inhibitors 4,027 (13.5) 1,805 (32.8) 2,222 (9.1) < 0.0001
ARBs 1,316 (4.4) 473 (8.6) 843 (3.5) < 0.0001
β-blockers 4,045 (13.5) 1,086 (19.7) 2,959 (12.1) < 0.0001
Calcium channel blockers 3,070 (10.3) 970 (17.6) 2,100 (8.6) < 0.0001
Diuretics 2,919 (9.8) 849 (15.4) 2,070 (8.5) < 0.0001
Index CV event type†
CABG 1,904 (6.4) 412 (7.5) 1,492 (6.1) 0.0002
Other CV procedure 8,613 (28.8) 1,417 (25.8) 7,196 (29.5) < 0.0001
Myocardial infarction 9,231 (30.9) 1,420 (25.8) 7,811 (32.1) < 0.0001
Heart failure 2,244 (7.5) 686 (12.5) 1,558 (6.4) < 0.0001
Angina 1,651 (5.5) 315 (5.7) 1,336 (5.5) 0.48
Other IHD 11,258 (37.7) 2,011 (36.6) 9,247 (38.0) 0.053
Ischemic stroke 2,634 (8.8) 552 (10.0) 2,082 (8.5) 0.0004
TIA/other CVA 2,324 (7.8) 395 (7.2) 1,929 (7.9) 0.07
PVD 164 (0.5) 38 (0.7) 126 (0.5) 0.12
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; CCI, Charlson Comorbidity Index; 
CV, cardiovascular; CVA, cerebrovascular accident; HMO, Health Maintenance Organization; IHD, ischemic heart disease; PPO, Preferred Provider 
Organization; PVD, peripheral vascular disease; TIA, transient ischemic attack.
*History of diabetes in the pre-index period. †Index hospitalization may be categorized into multiple events if it had both a cardiovascular diagnosis 
and procedure. ‡P-values for comparison of patients with vs. without diabetes; χ2 test for categorical variables, and t-test for continuous variablesCardiovascular Diabetology 2009, 8:53 http://www.cardiab.com/content/8/1/53
Page 6 of 11
(page number not for citation purposes)
betic patients. Cardiovascular-related pharmacy costs
(mean [SD]) during the follow-up period were also higher
for diabetic patients (Year 1: $964 [$1,060]; Year 2:
$2,049 [$2,007]; Year 3: $3,013 [$2,910]) compared with
non-diabetic patients (Year 1: $774 [$1,044]; Year 2:
$1,588 [$1,844]; Year 3: $2,406 [$2,477]).
In a multivariable GLM analysis adjusting for age, gender
and other patient characteristics, total cardiovascular-
related costs after 1-year follow-up were more likely to be
higher for patients with diabetes vs. those without diabe-
tes (adjusted relative risk = 1.28, 95% confidence interval
= 1.22-1.35, p < 0.0001).
Impact of diabetes on health-care resource use
Patients with diabetes had a mean (SD) LOS for the index
hospitalization of 4.8 (3.5) days compared with 4.3 (3.0)
days for non-diabetic patients (P < 0.0001) (Table 3). For
both study cohorts, the longest periods of index hospital-
ization were associated with CABG procedures (diabetics:
10.0 [3.9] days; non-diabetics: 9.0 [3.6] days), followed
by hospitalizations with a diagnosis of peripheral vascular
Table 2: Incidence of subsequent cardiovascular events in 1 year of follow-up by subsequent cardiovascular event type and diabetic 
status
Subsequent CV Event Type* Patients with Diabetes†‡
(n = 5,501)
Patients without Diabetes†‡
(n = 24,362)
P-value
(χ2 test)
CABG 147 (2.7) 425 (1.7) < 0.001
Other CV procedure 391 (7.1) 1,395 (5.7) < 0.001
Myocardial infarction 129 (2.3) 375 (1.5) < 0.001
Heart failure 197 (3.6) 425 (1.7) < 0.001
Angina 23 (0.4) 83 (0.3) 0.38
Other IHD 613 (11.1) 2,454 (10.1) 0.02
Ischemic stroke 105 (1.9) 300 (1.2) < 0.001
TIA/other CVA 76 (1.4) 212 (0.9) < 0.001
PVD 29 (0.5) 80 (0.3) 0.03
CABG, coronary artery bypass graft; CV, cardiovascular; CVA, cerebrovascular accident; IHD, ischemic heart disease; PVD, peripheral vascular 
disease; TIA, transient ischemic attack.
*Subsequent cardiovascular event may be categorized into multiple events if it had both a cardiovascular diagnosis and procedure.
†History of diabetes in the pre-index period. ‡All values are n (%).
P-values for comparison of patients with vs. without diabetes
Table 3: Mean direct medical costs and length of stay for the index cardiovascular hospitalization by index cardiovascular event type 
and diabetic status
Index CV Event 
Type*
Patients with Diabetes†
(n = 5,501)
Patients without Diabetes†
(n = 24,362)
No. of Patients Cost of Hospitali-
zation‡
Hospital LOS§ No. of Patients Cost of Hospitali-
zation‡
Hospital LOS§
All CV event types** 5,501 17,435 (21,613) 4.8 (3.5) 24,362 16,917 (20,342) 4.3 (3.0)
CABG 412 60,385 (38,622) 10.0 (3.9) 1,492 55,004 (32,109) 9.0 (3.6)
Other CV 
procedure
1,417 25,925 (19,369) 4.1 (2.4) 7,196 26,331 (21,446) 4.1 (2.4)
Myocardial 
infarction
1,420 26,035 (27,918) 5.2 (3.6) 7,811 24,802 (24,278) 4.6 (2.9)
Heart failure 686 11,178 (13,168) 5.7 (3.7) 1,558 12,560 (16,245) 5.6 (3.6)
Angina 315 7,038 (6,975) 2.9 (1.4) 1,336 6,878 (7,722) 2.7 (1.4)
Other IHD 2,011 17,869 (20,538) 4.2 (3.0) 9,247 14,740 (17,549) 3.7 (2.6)
Ischemic stroke 552 11,802 (12,025) 5.6 (3.7) 2,082 12,667 (13,344) 5.4 (3.3)
TIA/other CVA 395 6,638 (6,733) 4.0 (3.4) 1,929 6,711 (6,379) 3.7 (2.7)
PVD 38 19,432 (25,386) 8.1 (6.4) 126 15,315 (17,835) 6.6 (5.0)
CABG, coronary artery bypass graft; CV, cardiovascular; CVA, cerebrovascular accident; IHD, ischemic heart disease; LOS, length of stay; PVD, 
peripheral vascular disease; TIA, transient ischemic attack.
*Index hospitalization may be categorized into multiple events if it had both a cardiovascular diagnosis and procedure. †History of diabetes in the 
pre-index period. ‡Costs are mean (SD) per patient in US$. §Length of stay is mean (SD) in days. **For t-test comparisons of all CV event patients 
with vs. without diabetes, cost of hospitalization: P = 0.09, hospital length of stay: P < 0.0001Cardiovascular Diabetology 2009, 8:53 http://www.cardiab.com/content/8/1/53
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disease (diabetics: 8.1 [6.4] days; non-diabetics: 6.6 [5.0]
days) (Table 3).
For the first recurrent cardiovascular hospitalization,
mean (SD) LOS was 5.6 (12.6) days for patients with dia-
betes, compared with 4.6 (7.3) days for non-diabetics (P
= 0.0008) (Table 4). Recurrent hospitalizations with the
longest periods of inpatient stay for both study cohorts
were those with a diagnosis of transient ischemic attack or
other cerebrovascular accident and those involving CABG
procedures (Table 4).
Mean LOS for cardiovascular hospitalizations across 3
years of follow-up are shown in Table 5. With the excep-
tion of inpatient stays with a diagnosis of peripheral vas-
cular disease in the third year of follow-up, where data on
only 2 patients with diabetes were available, diabetic
patients had longer periods of follow-up hospitalization
for all cardiovascular event types assessed than patients
without diabetes (Table 5). The longest periods of follow-
up hospitalization for both study cohorts were those asso-
ciated with a diagnosis of heart failure (Table 5). Overall,
the total period of inpatient cardiovascular hospitaliza-
tion after 3 years of follow-up was 3.3 (12.4) days for
patients with diabetes compared with 1.8 (5.8) days for
non-diabetic patients (P < 0.0001).
Discussion
In this retrospective claims database analysis, we provide
quantitative documentation of the differential costs asso-
ciated with managing patients with diabetes hospitalized
for a cardiovascular event within US managed-care set-
tings. Our observations that the diabetic population
incurs higher direct medical costs for cardiovascular care
during the initial hospitalization and follow-up period
than their non-diabetic counterparts is not new; however,
in light of advances in medical care and the pertinence of
its setting (within a US managed care population), this
contemporary assessment is relevant. We confirm that
patients with diabetes also experience longer periods of
inpatient cardiovascular hospitalization than those with-
out diabetes. The higher costs and resource use in the dia-
betic cohort likely reflect the combination of a higher
incidence of subsequent cardiovascular events observed in
this population compared with patients without diabetes
as well as a higher overall comorbidity index. In addition
to evaluating the incremental costs and resource use asso-
ciated with cardiovascular events overall, this study is the
first of its kind to provide an economic assessment of this
nature for specific cardiovascular event types such as
CABG procedures, MI, and ischemic stroke.
Excess medical costs for the initial cardiovascular hospi-
talization in the diabetic cohort were primarily driven by
large cost differentials for those hospitalizations associ-
ated with CABG procedures, other ischemic heart disease
(eg, coronary atherosclerosis), and peripheral vascular
disease - CVD types commonly associated with diabetes.
During the follow-up period, diabetic patients experi-
enced a higher incidence of subsequent cardiovascular
events than the non-diabetic cohort for each event type
Table 4: Mean direct medical costs and length of stay for the first recurrent cardiovascular hospitalization by first Recurrent 
cardiovascular event type and diabetic status
First Recurrent CV 
Event Type*
Patients with Diabetes†
(n = 5,501)
Patients without Diabetes†
(n = 24,362)
No. of Patients Cost of Hospitali-
zation‡
Hospital LOS§ No. of Patients Cost of Hospitali-
zation‡
Hospital LOS§
All CV event types** 1,071 18,488 (22,014) 5.6 (12.6) 3,734 17,481 (22,895) 4.6 (7.3)
CABG 112 43,404 (28,686) 10.8 (33.6) 338 47,110 (39,612) 8.3 (7.1)
Other CV 
procedure
346 19,831 (14,867) 3.2 (2.3) 1,281 18,807 (15,588) 2.9 (2.6)
Myocardial 
infarction
106 22,854 (33,721) 8.2 (34.8) 332 22,125 (27,934) 5.1 (5.0)
Heart failure 168 14,031 (21,581) 7.5 (6.9) 363 14,398 (26,197) 5.7 (5.4)
Angina 18 8,016 (9,243) 3.9 (4.0) 72 8,477 (9,039) 3.2 (2.3)
Other IHD 554 21,445 (21,768) 4.3 (5.5) 2,316 18,038 (19,859) 3.6 (3.2)
Ischemic stroke 96 11,168 (8,687) 5.0 (4.0) 267 10,804 (10,594) 6.0 (8.3)
TIA/other CVA 64 7,501 (6,720) 10.0 (14.1) 179 9,195 (11,887) 12.8 (24.6)
PVD 25 23,146 (23,278) 7.6 (5.3) 61 14,788 (13,850) 4.9 (4.4)
CABG, coronary artery bypass graft; CV, cardiovascular; CVA, cerebrovascular accident; IHD, ischemic heart disease; LOS, length of stay; PVD, 
peripheral vascular disease; TIA, transient ischemic attack.
*First recurrent hospitalization may be categorized into multiple events if it had both a cardiovascular diagnosis and procedure. †History of diabetes 
in the pre-index period. ‡Costs are mean (SD) per patient in US$. §Length of stay is mean (SD) in days. **For t-test comparisons of all CV event 
patients with vs. without diabetes, cost of hospitalization: P = 0.20, hospital length of stay: P = 0.0008.Cardiovascular Diabetology 2009, 8:53 http://www.cardiab.com/content/8/1/53
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(Table 2). As such, medical costs for cardiovascular care
during the follow-up period were consistently higher in
the diabetic cohort. All cardiovascular event types exam-
ined in this analysis contributed to excess follow-up costs
in patients with diabetes, with cost differentials between
the diabetic and non-diabetic cohorts increasing with
each successive year of follow-up. Inpatient hospitaliza-
tion costs and costs associated with outpatient care, such
as physician office visits and imaging tests, were the pri-
mary drivers of follow-up cardiovascular costs irrespective
of diabetic status.
Taking into account expenditures for the initial cardiovas-
cular hospitalization plus all cardiovascular events during
Table 5: Cumulative total direct medical costs and length of stay for cardiovascular events during 3 years of follow-up by follow-up 
cardiovascular event type and diabetic status
Follow-up CV Event Type* Patients with Diabetes†
(n = 5,501)
Patients without Diabetes†
(n = 24,362)
No. of Patients Cost of
Follow-Up‡
Hospital LOS§ No. of Patients Cost of
Follow-Up‡
Hospital LOS§
1 Year:
All patients with CV events** 5,501 8,805 (22,277) 1.6 (7.4) 24,362 6,982 (18,545) 1.0 (4.8)
CABG 412 6,894 (13,122) 0.7 (2.8) 1,492 6,690 (13,159) 0.6 (2.8)
Other CV procedure 1,417 11,195 (19,917) 1.3 (3.7) 7,196 9,628 (22,946) 0.9 (3.5)
Myocardial infarction 1,420 12,256 (31,941) 1.7 (5.2) 7,811 9,502 (24,244) 1.1 (4.4)
Heart failure 686 9,324 (22,806) 3.3 (16.4) 1,558 8,711 (26,334) 1.9 (6.4)
Angina 315 5,463 (19,684) 0.6 (3.1) 1,336 3,985 (11,352) 0.4 (1.6)
Other IHD 2,011 8,053 (17,264) 1.2 (4.4) 9,247 6,167 (14,279) 0.8 (3.4)
Ischemic stroke 552 7,521 (13,388) 2.2 (7.0) 2,082 6,052 (11,827) 1.9 (9.4)
TIA/other CVA 395 3,648 (8,469) 0.9 (3.6) 1,929 2,544 (9,369) 0.6 (5.3)
PVD 38 8,537 (20,215) 2.5 (5.0) 126 6,163 (17,706) 0.9 (3.2)
2 Years:
All patients with CV events†† 2,132 13,860 (26,619) 2.3 (8.6) 9,522 10,056 (22,677) 1.3 (5.3)
CABG 155 10,161 (14,314) 2.3 (19.6) 589 10,313 (17,319) 0.9 (3.8)
Other CV procedure 560 17,980 (29,350) 2.5 (11.5) 2,806 13,980 (24,577) 1.2 (3.8)
Myocardial infarction 530 19,703 (37,992) 2.9 (12.1) 3,091 13,520 (27,764) 1.4 (5.1)
Heart failure 251 14,535 (27,065) 4.1 (11.6) 568 12,606 (35,669) 2.6 (8.2)
Angina 129 6,869 (13,410) 1.2 (4.0) 576 5,015 (11,391) 0.4 (1.7)
Other IHD 802 12,485 (20,869) 1.6 (4.4) 3,585 9,207 (18,789) 1.1 (3.8)
Ischemic stroke 211 12,893 (19,845) 3.4 (9.5) 694 8,686 (15,325) 1.9 (8.2)
TIA/other CVA 155 6,916 (14,687) 1.5 (7.3) 844 4,576 (15,012) 1.0 (7.8)
PVD 14 9,802 (14,433) 1.1 (3.3) 52 5,380 (10,697) 0.7 (2.0)
3 Years:
All patients with CV events‡‡ 735 16,149 (27,290) 3.3 (12.4) 3,141 12,163 (26,268) 1.8 (5.8)
CABG 54 14,299 (20,342) 5.6 (34.4) 189 11,445 (17,920) 1.1 (3.9)
Other CV procedure 174 21,821 (29,208) 4.2 (19.7) 864 17,150 (24,413) 1.5 (3.7)
Myocardial infarction 194 19,773 (32,653) 4.0 (18.9) 984 16,566 (33,829) 2.0 (6.0)
Heart failure 84 17,641 (33,665) 6.2 (17.5) 198 15,309 (40,834) 2.9 (7.0)
Angina 45 10,744 (19,220) 1.9 (6.6) 185 4,844 (9,124) 0.5 (1.5)
Other IHD 268 16,428 (25,001) 2.7 (5.8) 1,179 12,031 (21,739) 1.9 (6.3)
Ischemic stroke 71 13,654 (19,163) 3.3 (8.9) 242 8,526 (14,211) 1.8 (6.0)
TIA/other CVA 62 9,045 (21,836) 1.4 (4.2) 284 4,400 (10,622) 0.8 (3.8)
PVD 2 10,119 (10,258) 0.0 (0.0) 22 6,678 (14,186) 1.2 (2.6)
CABG, coronary artery bypass graft; CV, cardiovascular; CVA, cerebrovascular accident; IHD, ischemic heart disease; LOS, length of stay; PVD, 
peripheral vascular disease; TIA, transient ischemic attack.
*Follow-up cardiovascular event may be categorized into multiple events if it had both a cardiovascular diagnosis and procedure. †History of 
diabetes in the pre-index period. ‡Costs are incremental to that of the index cardiovascular hospitalization and given as mean (SD) per patient in 
US$. §Length of stay is mean (SD) in days.
**For t-test comparisons of all CV event patients with vs. without diabetes after 1 year cost of hospitalization: P < 0.0001, hospital length of stay: P 
< 0.0001; ††after 2 years, cost of hospitalization: P < 0.0001, hospital length of stay: P < 0.0001; ‡‡after 3 years, cost of hospitalization: P = 0.0002, 
hospital length of stay: P < 0.0001.Cardiovascular Diabetology 2009, 8:53 http://www.cardiab.com/content/8/1/53
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the follow-up period, the incremental per-patient cost
attached to cardiovascular events in patients with diabetes
was $10,131 over 3 years. Extrapolation of this additional
cost across the ~5,500 diabetic patients identified from
this health-care plan reveals that the 3-year excess cardio-
vascular costs for this population totaled nearly $56 mil-
lion, or > $18.5 million per year.
The majority of studies that have investigated the impact
of comorbid conditions on health-care expenditure for
diabetes have found that cardiovascular complications are
the most costly component of medical care in this popu-
lation [14-16,19,20]. For example, a recent model of the
lifetime costs of complications associated with diabetes
found that macrovascular disease accounted for 85% of
cumulative costs in the first 5 years and 52% of costs over
30 years [19].
Furthermore, we and others [14,15,18] have shown that
the cost of CVD is notably higher in diabetic patients com-
pared with similar patients without diabetes, likely due to
the severity of cardiovascular events experienced by dia-
betic individuals as indicated by a worse prognosis for sur-
vival [7-10]. A recent study [18] assessing annual medical-
care costs in diabetic patients from a large managed-care
organization found that patients with both diabetes and
CVD had higher medical-care costs than non-diabetic
patients with CVD ($10,172 versus $6,396 per patient per
year). These estimates are somewhat lower than the costs
obtained in our analysis, where annual costs per patient
for follow-up cardiovascular events were up to $16,149
for diabetic patients and $12,163 for non-diabetic
patients in the third year of follow-up. The higher costs
reported in our analysis in part reflects the fact that costs
are from 2006 (versus 1999 costs in the previous study).
Also, our analysis is based on actual costs paid by health-
care plan providers in the PharMetrics database, as
opposed to applying standard unit costs to resource-use
profiles in a not-for-profit health maintenance organiza-
tion, which may have the effect of underestimating the
cost of care of these patients relative to our setting.
Another study estimating direct medical costs associated
with an initial event and 1 year of follow-up care for spe-
cific cardiovascular complications in diabetic patients
found that the total event cost was $30,364 for MI; $6,024
for angina; $40,209 for ischemic stroke; and $3,874 for
TIA [20]. Although closer to our assessment of cardiovas-
cular costs in diabetic patients, these costs are still gener-
Total mean direct medical costs per patient over 3 years of follow up for all cardiovascular events (left-hand graph) and for  selected cardiovascular event types (right-hand graph) Figure 2
Total mean direct medical costs per patient over 3 years of follow up for all cardiovascular events (left-hand 
graph) and for selected cardiovascular event types (right-hand graph). CABG, coronary artery bypass graft; CV, car-
diovascular; DM, diabetes mellitus; MI, myocardial infarction. Data provided represent the mean total cumulative direct medical 
costs per patient for cardiovascular events across 3 years of follow-up for all cardiovascular events and for selected event 
types.
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ally lower than those obtained in our analysis, again likely
due to the use of standard unit costs from the year 2000.
As a retrospective analysis of a health-care plan claims
database, this study is not without limitations. The use of
diagnosis, procedure, and medication codes to identify
patients and assess downstream costs and resource use
relies on the accurate assignment of these codes to patient
records in order to faithfully capture an individual's med-
ical history. Contributions to the database used in this
analysis are subjected to data quality checks to ensure
minimal error rates. Furthermore, only health-care plans
that submitted data for all plan members are included in
the database, ensuring complete data capture and repre-
sentative samples. Another potential limitation of this
study is that the analysis of direct medical costs focuses
the interpretation of the results to a payor's perspective
and to US managed-care populations. However, the
records in this database are representative of the national,
commercially-insured population on a variety of demo-
graphic measures including age, gender, and plan type.
The data are also longitudinal, with an average member
enrollment time of 2 years. Hence, the results of this anal-
ysis may be generalized to similar managed-care popula-
tions at a nation-wide level.
Conclusion
The results of the current analysis demonstrate that the
incidence of subsequent events in the first year following
hospitalization for an initial cardiovascular episode is sig-
nificantly higher for patients with diabetes compared with
non-diabetic patients. As a consequence of this increased
cardiovascular burden, diabetic patients hospitalized for a
cardiovascular event incur higher costs for cardiovascular
care than their non-diabetic counterparts. The real-world
cost estimates described here will aid the development of
future economic models that assess the impact of health-
care initiatives aimed at this growing diabetic population.
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